The Montreux Healthcare Fund has completed the acquisition of Christchurch Group, previously ‘Project Lyra’. The market leading neuro-rehabilitation business will add £3.6m EBITDA to the fund’s portfolio with capacity of 136 beds. Headquartered in Northampton, the business comprises 10 facilities with 98% of the beds being freehold.

The Christchurch Group services are Headway accredited, the only provider in the country to receive this accolade across all of its sites, with all facilities expected to be rated Good or Outstanding by the Care Quality Commission.

The business will aim to deliver considerable value to the wider group, with several key staff retained at a senior level. The acquisition offers the opportunity to drive forward occupancy and offers plans for expansion of 22 additional organic beds in the medium term.

Oliver Harris, CEO, Montreux Capital Management (UK) stated: “The Christchurch Group acquisition is a step forward in the Montreux Healthcare Fund’s strategy, providing 136 high quality care beds with further expansion planned in the medium term. My team and I have worked hard to secure this acquisition in a short time frame and believe this will deliver good value to our investors.”

Find Us

Thameside House
Hurst Road
East Molesey
KT8 9AY

T: + 44 (0) 1932 860 140
E: info@montreuxcm.com

Information on this webpage relates to and is provided by Montreux Capital Management (UK) Limited

The content of this webpage should not be construed as financial advice. Any decision to invest should be made only on the basis of the relevant documentation for each investment. Past performance is not necessarily a guide to future performance. The value of an investment may go down as well as up and investors may not get back the full amount invested. Investments in small unquoted companies carry an above-average level of risk. These investments are highly illiquid and as such, there may not be a readily available market to sell such an investment. Montreux Capital Management (UK) Limited and Sapia Partners LLP (together “the Sponsors,” or “Sponsor”) do not provide specific individual advice on the suitability of investments with regard to a potential investor’s individual circumstances, risk tolerance or investment objectives and investors should seek independent financial advice if they are in any doubt whether a product is suitable for them.

Montreux Capital Management (UK) Limited is an Appointed Representative of Sapia Partners LLP which is authorised and regulated by the Financial Conduct Authority.

ACCEPT